2.4.2.12	drug development	inhibitor-soaking experiments	690246	
2.4.2.12	medicine	a dose of 75 mg/kg GMX1777, i.e. 1-[2-(2-(2-(2-methoxyethoxy)-ethoxy)ethoxy)-ethoxy-carbonyloxymethyl]-4-[N'-cyano-N''-(6-(4-chlorophenyl)-hexyl)-N-guanidino]pyridinium chloride, prodrug of GMX1778, administered over a 24 h intravenous infusion causes tumor regression in the IM-9 model, the SHP-77 model, and HCT-116 model. A 72 h continuous intravenous infusion is also effective in the IM-9 model, but is associated with smaller therapeutic index	701720	
2.4.2.12	medicine	a dose of 75 mg/kg GMX1777, i.e. 1-[2-(2-(2-(2-methoxyethoxy)-ethoxy)ethoxy)-ethoxy-carbonyloxymethyl]-4-[N'-cyano-N''-(6-(4-chlorophenyl)-hexyl)-N-guanidino]pyridinium chloride, prodrug of GMX1778, administered over a 24 h intravenous infusion produces GMX1778 steady-state plasma levels of about 1 microg/ml and causes nicotinamide dinucleotide levels to decrease significnantly in tumors. Nicotinic acid protects mice treated with a lethal dose of GMX1777	701720	
2.4.2.12	medicine	longevity enzyme for human SMCs	680749	
2.4.2.12	medicine	specific inhibition of enzyme transport into the nucleus might be a potential avenue for managing cancer	759503	
2.4.2.12	medicine	the enzyme is a therapeutic target in metastatic melanoma	760200	
2.4.2.12	pharmacology	enzyme is a potential target for development of anticancer drugs	661421	
2.4.2.12	pharmacology	NAMPT inhibition might have therapeutic efficacy in immune-mediated inflammatory diseases through impact on inflammatory cytokine secretion by leukocytes	694813